RxDoctor Payments Data

Renu Shishodia, MD

Psychiatry · Bakersfield, CANPI 1386785962

Payments from drug & device makers

$14,441in general payments, 2019–2025

Across 777 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$3K
  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$948
  • Johnson & Johnson$924
  • Otsuka America Pharmaceutical, Inc.$924
  • Neurocrine Biosciences, Inc.$885
  • plus $6K from 26 others

What the payments were for

  • Food & beverage$14,36299%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,441 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$9,823
Medicare patients
34
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide11$16,610
VraylarCariprazine Hcl12$16,609
Aripiprazole35$4,512
Trazodone Hcl143$2,079
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$1,748
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine46$1,712
Zolpidem Tartrate ErZolpidem Tartrate12$1,524
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine43$1,417
Buspirone Hcl45$1,075
Quetiapine Fumarate56$975
Bupropion Hcl23$881
Alprazolam115$848
Venlafaxine Hcl ErVenlafaxine Hcl33$814
Duloxetine Hcl44$780
Bupropion Hcl SrBupropion Hcl25$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$767$16,61011 claims
AbbVieVraylar$1,376$16,60912 claims
Almatica Pharma LLCSertraline Hcl$63$63855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →